Wockhardt spurts after collaboration with UK's Serum Life Sciences

Image
Capital Market
Last Updated : Mar 21 2022 | 10:16 AM IST

Wockhardt surged 9.51% to Rs 320.05 after the company and Serum Life Sciences UK announced collaboration for manufacturing multiple vaccines in the United Kingdom.

Serum Life Sciences UK is a subsidiary of the Serum Institute of India, one of the world's largest vaccine manufacturers to deliver a global vaccine programme.

The collaboration between a subsidiary of Wockhardt and Serum Life Sciences UK will help create considerable number of employment opportunities along with creation of new sterile fill and finish facility in Wrexham, North Wales ('new facility').

A profit sharing arrangement has been made between the two parties for this New Facility that will deliver an additional 150 million vaccine doses of multiple vaccines.

Wockhardt UK has manufactured a COVID-19 vaccine in collaboration with UK Government and AstraZeneca. Its collaboration with Serum Life Sciences is an addition to the earlier arrangement.

Wockhardt is a research based global pharmaceutical and biotech company, headquartered in India.

On a consolidated basis, Wockhardt reported net loss of Rs 6.78 crore in Q3 December 2021 as against net profit of Rs 15.24 crore in Q3 December 2020. Net sales rose 11.76% to Rs 853.89 crore in Q3 December 2021 over Q3 December 2020.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 21 2022 | 10:06 AM IST

Next Story